MedQUEST Reduces Hep C Restrictions

Press release applauding MedQUEST memo

In December 2022, the Hawaiʻi State Medicaid program (“MedQUEST”) sent out an updated memo on hepatitis C treatment to its providers and plans. The memo focuses on alignment with the AASLD/IDSA treatment guidance, specifically stating:

“The goal of this HCV policy is to assure adherence to the best practice guidance, currently outlined by the AASLD-IDSA HCV Guidance. For treatment regimens following the AASLD- IDSA HCV Guidance, there will be no prior authorization [emphasis added]”

This memo was draft and finalized, after a series of discussions and recommendations from members of our coalition 😊 We appreciate MedQUEST leaders for being such meaningful collaborators on this important issue.

Download the memo and read the press release.